Olof Sköldenberg

Olof Sköldenberg

Professor/Senior Physician
Visiting address: Entrévägen 2, 18257 Danderyd
Postal address: D1 Kliniska vetenskaper, Danderyds sjukhus, D1 Ortopedi, 182 88 Stockholm
Part of:

About me

  • Olof Sköldenberg is a Professor of Orthopaedics at the Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, and a senior consultant in orthopaedic surgery at Danderyd Hospital. Born in Stockholm in 1967, he began his medical career as a registered nurse in 1991 and became a surgical nurse in 1992. He completed his medical degree at Uppsala University in 1999 and became a specialist in orthopaedic surgery in 2010.

    He defended his PhD at Karolinska Institutet in 2010 and has since combined clinical practice with an active academic career at the Department of Clinical Sciences, Danderyd Hospital. He was appointed Associate Professor in 2014 and held an ALF-funded clinical postdoctoral position between 2014 and 2018. In June 2020, he was appointed Professor of Orthopaedics at Karolinska Institutet.

    Sköldenberg holds several national and international leadership roles in orthopaedics. He has served as Chairman of the Swedish Hip and Knee Society since 2018 and is currently Scientific Secretary of the Swedish Orthopaedic Association (since 2023/2024). He is also a member of the Scientific Committee of the European Hip Society (EHS) and participates in multiple international orthopaedic organisations focused on hip and knee arthroplasty.

    His clinical and academic work aims to improve outcomes in hip and knee replacement surgery through high-quality clinical trials, long-term follow-up studies, national register-based research, and methodological innovation.

Research

  • Olof Sköldenberg’s primary research focus is on large-scale clinical trials and evidence-based improvements in hip arthroplasty. His work encompasses randomized controlled trials, long-term follow-up studies and national register-based analyses, with strong emphasis on clinical relevance and patient-centered outcomes.

    Core interests and ongoing areas:

     

    Large multicentre trials in hip surgery (for instance participation in EPOS) with focus on prevention of surgical complications and optimisation of perioperative care. PubMed+2ResearchGate+2

    Implant selection and comparative implant performance (e.g. cup/liner design, polyethylene quality) in primary total hip arthroplasty. PubMed+2pdfs.semanticscholar.org+2

    Long-term implant survival, bone mineral density around implants, and bone remodelling / periprosthetic osteolysis. Karolinska Institutet+1

    Postoperative outcomes including early mortality, adverse events and periprosthetic fractures — studied with register data and multicentre cohort methodology. PubMed+2ResearchGate+2

    Methodological innovation — including use of national registries and advanced imaging analytics (e.g. AI for radiographic analysis) to improve diagnosis, follow-up and outcome monitoring of arthroplasty patients. news.ki.se+1

    The overarching goal of his research is to generate high-level evidence that can guide best practices in hip (and knee) arthroplasty, thereby improving outcomes and long-term quality of life for patients undergoing joint replacement.

Teaching

  • Olof Sköldenberg is actively involved in undergraduate, postgraduate, and specialist training in orthopaedics at Karolinska Institutet and Danderyd Hospital. He teaches medical students, supervises specialist trainees in orthopaedic surgery, and mentors PhD students focusing on clinical and register-based orthopaedic research.

    His teaching includes trauma and arthroplasty surgery, evidence-based clinical practice, perioperative management, and methodological aspects of orthopaedic research. He has supervised several doctoral students, contributed to curriculum development in clinical orthopaedics, and regularly lectures at national and international courses and professional meetings.

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2024 - 31 December 2025
    Purpose and aims: Our overarching goal is to reduce the risk of the most-dreaded post-operative complication of total hip replacement (THR) – prosthetic joint infection (PJI). This project involves a nationwide, randomized, placebo-controlled, double-blinded clinical drug trial to test the hypothesis that antibiotic-impregnated bone graft (AIBG) reduces the risk for PJI in THR with bone graft.Survey of the field: The administration of local antibiotics as a complement to systemic antibiotic treatment has become popular in complex THR. The advantage over standard systemic treatment is that high local concentrations of antibiotics can be achieved that inhibit perioperative colonization of the implant, thereby avoiding systemic toxicity and development of antibiotic resistance. However, to support the clinical use of AIBG a pivotal trial is needed.Organization, time plan and methods: Within 2 years, we will establish a nationwide study group (orthopedic surgeons, infection specialists, microbiologists and patient representatives) and analyze results from a pilot study to facilitate implementation of the full study. All hospitals using bone graft will be invited to participate.Patients: THR with bone graftIntervention: AIBGControl: SalineOutcome: risk of PJIThe exact dosing of the antibiotics and serum levels (safety assessment) will be determined during Year 1.Importance: To test if AIBG can reduce the risk for PJI in THR and avoiding development of antibiotic resistance.
  • Swedish Research Council
    1 January 2022 - 31 December 2025
    Rational for conducting the study: The most commonly used treatment of displaced femoral neck fracture in the elderly is hemiarthroplasty which provides a reliable clinical result. Deep periprosthetic joint infection (PJI) is a severe complication associated with an increased morality and often leads to major and repeated reoperations. PJI has been reported to occur in 2-4% of hemiarthroplasties after fracture. The aim of the trial is to investigate whether the risk of PJI is reduced after the use of dual impregnated antibiotic laden bone cement.Study design: Register-based, cluster randomized controlled trial.Population: Number of patients: 7,312. Inclusion criteria: Patients aged ≥60 year, with a displaced femoral neck fracture and eligible for hemiarthroplasty according to local guidelines. Exclusion criteria: Previous inclusion of contralateral hip. Pathological or stress fracture of the femoral neck or fracture adjacent to a previous ipsilateral hip implant.Intervention: Dual-impregnated antibiotic laden bone cement.Control: Single-impregnated antibiotic laden bone cement.Outcome: Primary outcome variable is the incidence of PJI within one year. Secondary outcome variables include the occurrence of re-operations for any reason, mortality,and health care costs. Future benefit and clinical application: A reduction of PJI could decrease the morbidity and mortality of this elderly population and reduce the need for reoperations and antibiotic treatment.
  • Swedish Research Council for Environment Agricultural Sciences and Spatial Planning
    1 January 2022 - 31 December 2025
    COVID-19 Coronavirus Pandemic has a devastating social and economic impact on humans leaving hundreds of millions of people at risk of extreme poverty. Until April 1st 2021, more than 129 million people have been infected, and nearly 2.9 million deaths have been reported worldwide. In only a year, the coronavirus pandemic has wiped out decades of global development in everything from health to economy and beyond.The COVID-19 pandemic also reveals shortcomings in emergency preparedness around the world. In the case of similar virus outbreaks, there will be an urgent need for a fast and effective method to increase the capacity of hospital isolation rooms and intensive care units to cope with the influx of patients. The present project aims at creating and designing a novel cost-effective, flexible and easy-to-implement solution for upgrading standard patient rooms to simplified isolation rooms (AIIR) for airborne infection. To that end: (I) A local ventilation exhaust will be designed, optimized, and implemented to remove emitted respiratory droplets from the hospitalized patients. Also (II) we will avoid leakage out of the room using an additional ventilation system smartly integrated into the standard patient room. Finally (III) we will combine the first two steps and verify the system (proof-of-concept) in laboratory measurements with industry participation. The solution will be used both for new construction and retrofitting of hospital buildings.
  • Swedish Research Council
    1 January 2019 - 31 December 2022
  • Swedish Research Council
    1 January 2019 - 31 December 2021

Employments

  • Professor/Senior Physician, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2020-

Degrees and Education

  • Docent, Orthopaedics, Karolinska Institutet, 2014
  • Degree Of Doctor Of Philosophy, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2010

News from KI

Events from KI